11.02.2021 23:28:21
|
US Federal Court Upholds Appeal In Favor Of Regeneron, Sanofi On Praluent
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) Thursday announced that the United States Court of Appeals for the Federal Circuit upheld the decision by the U.S. District Court for the District of Delaware that Amgen's asserted patent claims directed toward PCSK9 antibodies are invalid based on lack of enablement.
The Federal Circuit ruling means that Regeneron and Sanofi have successfully invalidated all five of Amgen's asserted claims relevant to Praluent (alirocumab).
"We are pleased with today's decision by the Federal Circuit, which affirms our longstanding position that Amgen's patents claiming PCSK9 antibodies purely by their function are overly broad and invalid," said Joseph LaRosa, Executive Vice President, General Counsel and Secretary, Regeneron. "Praluent was developed using Regeneron's proprietary technology, and the Federal Circuit validated that Amgen has no claim to Praluent or its development, helping to provide closure on this matter."
This decision follows the October 2020 ruling by the European Patent Office's Technical Board of Appeal that also invalidated certain functional claims of Amgen's European patent directed to PCSK9 antibodies.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Regeneron Pharmaceuticals Inc.mehr Nachrichten
14.03.25 |
Zuversicht in New York: NASDAQ 100 zum Ende des Freitagshandels im Plus (finanzen.at) | |
14.03.25 |
Börse New York: Das macht der S&P 500 aktuell (finanzen.at) | |
14.03.25 |
Aufschläge in New York: NASDAQ 100 zeigt sich am Freitagnachmittag fester (finanzen.at) | |
14.03.25 |
Aufschläge in New York: NASDAQ 100 am Freitagmittag stärker (finanzen.at) | |
14.03.25 |
Gute Stimmung in New York: S&P 500-Anleger greifen am Mittag zu (finanzen.at) | |
14.03.25 |
NASDAQ-Handel: NASDAQ 100 verbucht zum Start des Freitagshandels Zuschläge (finanzen.at) | |
12.03.25 |
NASDAQ-Handel: NASDAQ 100 beendet die Sitzung im Plus (finanzen.at) | |
12.03.25 |
Pluszeichen in New York: Anleger lassen NASDAQ 100 am Nachmittag steigen (finanzen.at) |
Analysen zu Regeneron Pharmaceuticals Inc.mehr Analysen
Aktien in diesem Artikel
Regeneron Pharmaceuticals Inc. | 609,80 | -1,39% |
|